Trials
4 active
4 in total · 3 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “CTX112 is a CD19-directed T-cell immunotherapy comprised of allogeneic T cells genetically modified ex vivo using CRISPR-Cas9 gene editing components”In the company’s words, NCT07804004 on ClinicalTrials.gov
- Tested for
- Progressive Multiple Sclerosis (PMS), Neuromyelitis Optica, Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease, Autoimmune Encephalitis, Stiff-Person Syndrome, B-cell Lymphoma, Non-Hodgkin Lymphoma, B-cell Malignancy and 16 more
- Main trialPhase 1/2
- “This is a single-arm, open-label, multicenter, ascending dose Phase 1/2 trial evaluating the safety and preliminary efficacy of CTX112 in adult participants with neurological autoimmune diseases (AIDs), including Progressive Multiple Sclerosis, relapsing Neuromyelitis Optica Spectrum Disorder, relapsing Myelin Oligodendrocyte Glycoprotein Antiody-Associated Disease, refractory AutoImmune Encephalitis, and refractory Stiff Person Syndrome”In the company’s words, NCT07804004 on ClinicalTrials.gov
- Other names
- Zugocabtagene geleucel · zugo-cel
Other drugs for Progressive Multiple Sclerosis (PMS)
- TolebrutinibSanofi · Phase 3
- OrelabrutinibBeijing InnoCare Pharma Tech Co., Ltd. · Phase 3
- RemibrutinibNovartis · Phase 3
- FenebrutinibRoche · Phase 3
- KYV-101Kyverna Therapeutics · Phase 2
- SUN-627Sundance Biosciences, Inc. · Phase 2
Coming up4
- 30 Dec 2029Phase 1/2 trial completes · ClinicalTrials.gov
- Jan 2030Phase 1/2 trial completes · ClinicalTrials.gov
- 31 Dec 2031Phase 1 trial completes · ClinicalTrials.gov
- Dec 2033Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Not yet recruiting | 30 Dec 2029 | A Safety and Efficacy Study Evaluating CTX112 in Subjects With Refractory Neurologic Autoimmune Disease | |
| Phase 1/2Recruiting | Jan 2030 | A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies | |
| Phase 1/2Recruiting | Dec 2033 | Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease | |
| Phase 1Recruiting | 31 Dec 2031 | A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026